|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Is osteoporosis a peculiar association with primary biliary cirrhosis?显示文摘AIM: (1) To compare the prevalence of osteoporosis (t-score ≤-2.5 SD) between stage Ⅳ PBC patients, and two groups of age- and sex-matched controls: one with hepatitis C virus (HCV)-related cirrhosis, and the other one consisting of a group of healthy subjects from the general population; (2) to identify the main risk factors for the development of bone loss.METHODS: Thirty-five stage Ⅳ PBC patients (mean age 52.5±10 years), 49 females with HCV-related cirrhosis (mean age 52.9±5.8 years) and 33 healthy females (mean age 51.8+2.22 years) were enrolled in the study. Bone metabolism was evaluated by measuring serum calcium corrected for serum albumin (Ca corr.), 25-hydroxy vitamin D (25-OH vit D), parathyroid hormone, osteocalcin.Bone mineral density (BMD) was assessed at the lumbar spine by dual-photon X-ray absorptiometry.RESULTS: Osteoporosis was present in 5/35 PBC patients (14.2%) and in 7/49 HCV-related cirrhotic patients (14.3%),without any statistical difference between the two groups.Among healthy control subjects, none had osteoporosis.No difference was found between the three groups in serum parameters of bone metabolism. Univariate analysis showed that menopausal state and low BMI were significantly correlated with osteoporosis. Multivariate regression analysis showed that menopausal status, BMI <23, and old age were independent variables significantly correlated with osteoporosis.CONCLUSION: PBC in itself has no negative influence on BMD. End-stage liver disease patients carry a disease-specific risk for osteoporosis, but have an effective risk of bone loss in relation to individual potential risk for each patient. A practical message should be taken into account, that is, every effort should be made to prevent osteoporosis when a patient has simple osteopenia, or if it is a woman in or near menopausal age. | Annarosa Floreani Andrea Mega Valentina Camozzi Vincenzo Baldo Mario Plebani Patrizia Burra Giovanni Luisetto | 2005 | World Journal of Gastroenterology2005，11，34： | 7 |
| 2 | pregnane X receptor and constitutive androstane receptor modulate differently CYp3A-mediated metabolism in earlyand late-stage cholestasis显示文摘AIM To ascertain whether cholestasis affects the expression of two CYP3 A isoforms(CYP3 A1 and CYP3 A2) and of pregnane X receptor(PXR) and constitutive androstane receptor(CAR).METHODS Cholestasis was induced by bile duct ligation in 16 male Wistar rats; whereas 8 sham-operated rats were used as controls. Severity of cholestasis was assessed on histological examination of liver sections, and serum concentrations of albumin, AST, ALT, GGT, ALPK and bilirubin. Gene and protein expressions of PXR, CAR, CYP3 A1 and CYP3 A2 were assessed by means of q RT-PCR and Western blot, respectively. Alterations in CYP3 A activity were measured by calculating the kinetic parameters of 4-OH and 1'-OH-midazolam hydroxylation, marker reactions for CYP3 A enzymes.RESULTS The m RNA and protein expression of CYP3 A1 increased significantly in mild cholestasis(P < 0.01). At variance, m RNA and protein expression of CYP3 A2 didn't change in mild cholestasis, whereas the expression and activity of both CYP3 A1 and CYP3 A2 decreased dramatically when cholestasis became severe. Consistently with these observations, the nuclear expression of both PXR and CAR, which was measured because they both translocate into the cell nucleus after their activation, virtually disappeared in the late stage of cholestatic injury, after an initial increase. These results indicate that early-and late-stage cholestasis affects CYP3 Amediated drug metabolism differently, probably as consequence of the different activation of PXR and CAR.CONCLUSION Early-and late-stage cholestasis affects CYP3 Amediated drug metabolism differently. PXR and CAR might be targeted therapeutically to promote CYP3 Amediated liver detoxification. | Daniela Gabbia Arianna Dalla Pozza Laura Albertoni Roberta Lazzari Giorgia Zigiotto Maria Carrara Vincenzo Baldo Tatjana Baldovin Annarosa Floreani Sara De Martin | 2017 | World Journal of Gastroenterology2017，23，42： | 5 |
| 3 | 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis显示文摘AIM:To compare the mucosal concentrations of 5-aminosalicylic acid(5-ASA)resulting from different pharmaceutical formulations and analyse the influence of inflammation on the mucosal concentrations.METHODS:The study included 130 inflammatory bowel disease(IBD)patients receiving 5-ASA as pH-dependent-release formulations(73 patients),time-dependent-release formulations(11 patients),or pro-drugs(18patients).In addition,28 patients were receiving topical treatment(2-4 g/d)with pH-dependent-release formulations.Endoscopic biopsies were obtained from the sigmoid region during the colonoscopy.The 5-ASA concentrations(ng/mg)were measured in tissue homogenatesusing high-pressure liquid chromatography with electrochemical detection.The t test and Mann-Whitney test,when appropriate,were used for statistical analysis.RESULTS:Patients receiving pH-dependent-release formulations showed significantly higher mucosal concentrations of 5-ASA(51.75±5.72 ng/mg)compared with patients receiving pro-drugs(33.35±5.78 ng/mg,P=0.01)or time-dependent-release formulations(38.24±5.53 ng/mg,P=0.04).Patients with endoscopic remission had significantly higher mucosal concentrations of5-ASA than patients with active disease(60.14±7.95ng/mg vs 35.66±5.68 ng/mg,P=0.02).Similar results were obtained when we compared patients with the histological appearance of remission and patients with active histological inflammation(67.53±9.22 ng/mg vs 35.53±5.63 ng/mg,P<0.001).Significantly higher mucosal concentrations of 5-ASA were detected in patients treated with both oral and topical treatments in combination compared with patients who received oral treatment with pH-dependent-release formulations alone(72.33±11.23 ng/mg vs 51.75±5.72 ng/mg,P=0.03).CONCLUSION:IBD patients showed significant variability in mucosal 5-ASA concentrations depending on the type of formulation,and the highest mean concentration was achieved using pH-dependent-release formulations. | Renata D’Incà Martina Paccagnella Romilda Cardin Surajit Pathak Vincenzo Baldo Maria Cecilia Giron Giacomo Carlo Sturniolo | 2013 | World Journal of Gastroenterology2013，19，34： | 4 |
| 4 | Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis显示文摘 | Ordog T Baldo M Danko R | 2000 | Diabetes2000，49，10： | 2 |
| 5 | Familial and Territorial Values for Sustainable Entrepreneurship in Italy: Some Reflections in Theory and Practice]显示文摘 | Mara Del Baldo | 2012 | Journal of Modern Accounting and Auditing2012，8，8： | 2 |
| 6 | Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response显示文摘 | Annarosa Floreani Nora Cazzagon Deris Gianni Boemo Tatjana Baldovin Vincenzo Baldo Joel Egoue Sara Antoniazzi Eliseo Minola | 2011 | European Journal of Gastroenterology & Hepatology2011，，11： | 2 |
| 7 | Neutron Stars and the Transition to Color Superconducting Quark Matter 显示文摘 | Baldo M Buballa M Burgio G F | 2003 | Phys Lett B2003，562，34： | 1 |
| 8 | High efficient phosphorescent emission from organic electroluminescent diodes 显示文摘 | Baldo M A O'brien D F | 1998 | Nature1998，395，： | 1 |
| 9 | Effects of the river discharge management on the nursery function of the Guadalquivir river estuary (SW Spain) 显示文摘 | DELGADO C F BALDO F VILAS C | 2007 | Hydrobiologia2007，587，1： | 1 |
| 10 | Incidence of pertussis in persons < 15 years of age in Valencia, Spain: seroprevalence of antibodies to pertussis toxin (PT) in children, adolescents and adults 显示文摘 | Javier Diez-Domingo Alfredo Ballester Jose'-Marl'a Baldo | 2004 | Journal of Infection2004，49，3： | 1 |
| 11 | Highly efficient phosphorescent emission from organic electroluminescent devices 显示文摘 | Baldo M A O′Brien D F You Y | 1998 | Nature1998，395，10： | 1 |
| 12 | Tomato SNP discovery by EST mining and resequencing显示文摘 | LABATE J A BALDO A M | 2005 | Molecular Breeding2005，16，4： | 1 |
| 13 | Highly efficient phosphorescent emission from organic electroluminescence devices显示文摘 | Baldo M A O'Brien D F You Y Shoustikov A Sibley S Thompson M E Forret S R | | 0，，： | 1 |
| 14 | Development and testing of a 10-kA hybrid mechanical-static DC circuit breaker显示文摘 | Novello L Baldo F Ferro A | 2011 | IEEE Transactions on Applied Superconductivity2011，21，6： | 1 |
| 15 | Tacrolimus ointment in the management of atopic dermatitis显示文摘 | Baldo A Cafiero M Di Caterino P | 2009 | Clin Cosmet Investing Dermatol2009，2，： | 1 |
| 16 | Experimental evaluation of high performance base course and road base asphalt con- crete with electric arc furnace steel slags 显示文摘 | Marco Pasetto Nicola Baldo | 2010 | Journal of Hazardous Materials2010，181，： | 1 |
| 17 | Highly efficient phosphorescent emission from organic electroluminescent devices 显示文摘 | BALDO M A O'BRIEN D F YOU Y | 1998 | Nature1998，395，： | 1 |
| 18 | A framework for computer-assisted creation of dy- namic virtual organisations 显示文摘 | Camarinha-Matos LM Oliveira AI Sesana M Galeano N Demsar D Baldo F | 2009 | International Journal of Production Re- search2009，47，17： | 1 |
| 19 | Health care service usage and costs for high-needs elderly patients with heart failure显示文摘Heart failure(HF)has been defined as global disease of pandemic proportions,since it affects around 26 million people worldwide.[1]According to a recent study,age is the most important factor influencing the prevalence of HF,as it is for most other chronic conditions.[2]This means that,with the predicted aging of the population(the proportion of the world’s population aged 60 years and over will nearly double from 2015 to 2050),[3]there will be a growth in the total burden of HF,and a rise in the number of comorbidities in HF patients.According to a recent study,almost 86%of adults with HF have two or more comorbid conditions.[4]Comorbidity,defined as the co-existence of one or more additional conditions in individuals with a specified index medical condition,[5]adds to the complexity of treating elderly patients with HF. | Alessandra Buja Riccardo Caberlotto Carlo Pinato Giulia Grotto Maria Chiara Corti Francesco Avossa Elena Schievano Vincenzo Baldo | 2020 | Journal of Geriatric Cardiology2020，17，9： | 1 |
| 20 | High-efficiency organic electrophosphorescent devices with Ir (ppy) 显示文摘 | Adachi C Baldo M A Forrest S R | 2000 | Appl Phys Lett2000，77，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员